That opportunity is now supported by manufacturing commitments, including Novo Nordisk's March 2026 announcement of a EUR 432 million expansion in Athlone, Ireland, to increase capacity for oral GLP-1 therapies, alongside Eli Lilly's November 2025 plan to build a USD 3 billion manufacturing facility in Katwijk, the Netherlands, aimed at oral medicines including the GLP-1 receptor agonist orforglipron
Many of you might notice a major improvement when they start eliminating dairy, excess sugar, gluten, alcohol, and processed and packaged foods for a given period
Its primary claim to fame is its ability to accelerate wound healing and tissue repair
Insurance coverage for liraglutide and semaglutide varies significantly depending on your insurance plan and the health condition being treated
This low dose helps the body adjust to the medication and minimizes potential side effects